Factor XIa inhibitors
View Patent ↗The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
1. A compound of the formula:
wherein
is a 5 or 6 membered heteroaryl ring, wherein said heteroaryl ring is optionally substituted with one to three substituents independently selected from the group consisting of nitro, cyano, oxo, R a , (C═O)R 4 , (C═O)OR 4 , NR 4 R 5 , NH(C═O)R 4 , NH(C═O)OR 4 , SO 2 R 4 , SO 2 NR 4 R 5 , NR 4 SO 2 R 5 and PO 3 R 4 ;
R 1 is aryl, heteroaryl, C 3-6 cycloalkyl or heterocyclyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups are optionally substituted with one to three substituents independently selected from the group consisting of halo, nitro, cyano, oxo, R 4 , OR 4 , (C═O)R 4 , (C═O)OR 4 , NR 4 R 5 , NH(C═O)R 4 , NH(C═O)OR 4 , C 3-6 cycloalkyl and heteroaryl which is optionally substituted with R 4 ;
R 2 is hydrogen or CH(R 2a )(R 2b );
R 2a is hydrogen, C 1-6 alkyl, aryl, heteroaryl, C 3-6 cycloalkyl, heterocyclyl or (C═O)NR 4 R 5 , wherein said alkyl group is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxy and cyano, and wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups are optionally substituted with one to three substituents independently selected from the group consisting of halo, nitro, cyano, oxo, R 4 and OR 4 ;
R 2b is hydrogen or C 1-6 alkyl, which is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxy and cyano;
R 3 is halo, cyano, (C═O)OR 4 or R 6 ;
R 4 is hydrogen or C 1-6 alkyl, which is optionally substituted with one to three groups independently selected from the group consisting of halo and hydroxy;
R 5 is hydrogen or C 1-6 alkyl, which is optionally substituted with one to three groups independently selected from the group consisting of halo and hydroxy;
R 6 is aryl, heteroaryl, C 3-10 cycloalkyl or heterocyclyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups are optionally substituted with one to three substituents independently selected from the group consisting of halo, nitro, cyano, oxo, R 4 , OR 4 , (C═O)R 4 , (C═O)OR 4 , (C═O)NR 4 R 5 , NR 4 R 5 , NH(C═O)R 4 , NH(C═O)OR 4 , SO 2 R 4 , SO 2 NR 4 R 5 , NR 4 SO 2 R 5 and PO 3 R 4 ;
R a is hydrogen, halo, R 4 or OR 4 ;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 of the formula:
wherein R 1 is aryl, heteroaryl, C 3-6 cycloalkyl or heterocyclyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups are optionally substituted with one to three substituents independently selected from the group consisting of halo, nitro, cyano, oxo, R 4 , OR 4 , (C═O)R 4 , (C═O)OR 4 , NR 4 R 5 , NH(C═O)R 4 , NH(C═O)OR 4 , C 3-6 cycloalkyl and heteroaryl which is optionally substituted with R 4 ;
R 2a is hydrogen, C 1-6 alkyl, aryl, heteroaryl, C 3-6 cycloalkyl, heterocyclyl or (C═O)NR 4 R 5 , wherein said alkyl group is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxy and cyano, and wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups are optionally substituted with one to three substituents independently selected from the group consisting of halo, nitro, cyano, oxo, R 4 and OR 4 ;
R 2b is hydrogen or C 1-6 alkyl, which is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxy and cyano;
R 3 is halo, cyano, (C═O)OR 4 or R 6 ;
R 4 is hydrogen or C 1-6 alkyl, which is optionally substituted with one to three groups independently selected from the group consisting of halo and hydroxy;
R 5 is hydrogen or C 1-6 alkyl, which is optionally substituted with one to three groups independently selected from the group consisting of halo and hydroxy;
R 6 is aryl, heteroaryl, C 3-10 cycloalkyl or heterocyclyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups are optionally substituted with one to three substituents independently selected from the group consisting of halo, nitro, cyano, oxo, R 4 , OR 4 , (C═O)R 4 , (C═O)OR 4 , (C═O)NR 4 R 5 , NR 4 R 5 , NH(C═O)R 4 , NH(C═O)OR 4 , SO 2 R 4 , SO 2 NR 4 R 5 , NR 4 SO 2 R 5 and PO 3 R 4 ;
R a is hydrogen, halo, C 1-3 alkyl or O(C 1-3 alkyl);
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 wherein R 1 is aryl, which optionally is substituted with one to three substituents independently selected from the group consisting of halo, cyano, R 4 , OR 4 and heteroaryl which is optionally substituted with R 4 ; or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 wherein R 1 is phenyl, which optionally is substituted with one to two substituents independently selected from the group consisting of halo and tetrazolyl; or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 wherein R 2a is aryl, which optionally is substituted with one to three halo groups; or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 wherein R 2a is phenyl, which optionally is substituted with halo; or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 wherein R 2b is hydrogen; or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 wherein R 2a is cyclopropyl; or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1 wherein R 3 is R 6 , which optionally is substituted with halo, (C═O)OR 4 or NH(C═O)OR 4 , or a pharmaceutically acceptable salt thereof.
10. The compound of claim 1 selected from:
or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
12. A method for inhibiting thrombus formation in blood or treating thrombus formation in blood comprising administering a composition of claim 11 to a mammal in need of thereof.
13. A method for preventing thrombus formation in blood comprising administering a composition of claim 11 to a mammal in need thereof.
14. A method of treating venous thromboembolism and pulmonary embolism in a mammal comprising administering a composition of claim 11 to a mammal in need thereof.
15. A method of treating deep vein thrombosis in a mammal comprising administering a composition of claim 11 to a mammal in need thereof.
16. A method of treating thromboembolic stroke in a human comprising administering a composition of claim 11 to a mammal in need thereof.